Sec Form 4 Filing - Liu Tony @ Cellular Biomedicine Group, Inc. - 2021-02-19

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Liu Tony 2. Issuer Name and Ticker or Trading Symbol Cellular Biomedicine Group, Inc. [ CBMG] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CEO, CFO (Last) (First) (Middle) C/O CELLULAR BIOMEDICINE GROUP, INC., 9605 MEDICAL CENTER DR, SUITE 100 3. Date of Earliest Transaction (MM/DD/YY) 02/19/2021 (Street) ROCKVILLE, MD20850 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/19/2021( 1 ) A( 2 ) 240,000 A $ 0 487,517 D Common Stock 02/19/2021 J 476,817 D 10,700 D Common Stock 02/19/2021 D 10,700 D 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option (Right to Buy) $ 7.23 02/19/2021 J 5,300 ( 5 ) 03/05/2023 Common Stock 5,300 ( 6 ) 0 D Employee Stock Option (Right to Buy) $ 5 02/19/2021 J 255,000 ( 7 ) 01/03/2024 Common Stock 255,000 ( 6 ) 0 D Employee Stock Option (Right to Buy) $ 20.63 02/19/2021 J 15,000 ( 8 ) 07/23/2021 Common Stock 15,000 ( 6 ) 0 D Employee Stock Option (Right to Buy) $ 20.63 02/19/2021 J 15,000 ( 9 ) 08/14/2021 Common Stock 15,000 ( 6 ) 0 D Employee Stock Option (Right to Buy) $ 15.53 02/19/2021 J 105,800 ( 10 ) 12/31/2021 Common Stock 105,800 ( 6 ) 0 D Employee Stock Option (Right to Buy) $ 35.53 02/19/2021 J 30,000 ( 11 ) 04/06/2025 Common Stock 30,000 ( 6 ) 0 D Employee Stock Option (Right to Buy) $ 20 02/19/2021 J 40,000 ( 12 ) 04/11/2026 Common Stock 40,000 ( 6 ) 0 D Employee Stock Option (Right to Buy) $ 12.55 02/19/2021 J 30,000 01/21/2017 01/21/2027 Common Stock 30,000 ( 6 ) 0 D Employee Stock Option (Right to Buy) $ 12.4 02/19/2021 J 120,000 ( 13 ) 03/03/2027 Common Stock 120,000 ( 6 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Liu Tony C/O CELLULAR BIOMEDICINE GROUP, INC. 9605 MEDICAL CENTER DR, SUITE 100 ROCKVILLE, MD20850 X CEO, CFO Signatures /s/Bizuo (Tony) Liu 02/19/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 11, 2020, by and among Cellular Biomedicine Group, Inc. (the "Company"), CBMG Holdings ("Parent") and CBMG Merger Sub Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company, with the Company surviving the Merger as a wholly-owned subsidiary of Parent (the "Merger"). The Merger became effective on February 19, 2021 (the "Closing Date"). ( 2 )Effective March 3, 2017, the Reporting Person was granted performance-based restricted stock units, which, as a result of the Merger, were accelerated and vested in full at the maximum level of performance on the Closing Date. ( 3 )Pursuant to an agreement between the Reporting Person and Parent, 476,817 shares of common stock held by the Reporting Person were converted into shares of common stock of Parent. ( 4 )Pursuant to terms of the Merger Agreement, at the effective time of the Merger, 10,700 shares of common stock of held by the Reporting Person were cancelled and exchanged for the right to receive merger consideration of $19.75 in cash per share. ( 5 )This option vested over a period of three years according to the following schedule: 1/36th per month following the vesting commencement date of March 5, 2013. ( 6 )Pursuant to an agreement between the Reporting Person and Parent, the 616,100 stock options held by the Reporting Person were converted into an option to acquire ordinary shares of Parent. ( 7 )This option vested over a period of three years according to the following schedule: 1/36th per month following the vesting commencement date of January 3, 2014. ( 8 )This option vested over a period of three years according to the following schedule: 1/3 on July 23, 2015 and 1/3 on each anniversary thereafter. ( 9 )This option vested over a period of three years according to the following schedule: 1/3 on August 14, 2015 and 1/3 on each anniversary thereafter. ( 10 )This option vested over a period of three years according to the following schedule: 1/3 on December 31, 2015 and 1/3 on each anniversary thereafter. ( 11 )This option vested according to the following schedule: 9,000 shares vested and became fully exercisable on April 6, 2016, 9,000 shares vested and became fully exercisable on April 6, 2017, and 12,000 shares vested and became fully exercisable on April 6, 2018. ( 12 )This option vested according to the following schedule: 12,000 shares vested and became fully exercisable on April 11, 2017; 12,000 shares vested and became fully exercisable on April 11, 2018; and 16,000 shares vested and became fully exercisable on April 11, 2019. ( 13 )This option vests over a period of four years according to the following schedule: 1/48th per month, with the first installment vested on March 27, 2017. In connection with the Merger, unvested options were accelerated and vested in full at the effective time of the Merger.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.